Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the ‘Mario Negri’ Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group

The aim of the study was to evaluate the role of epidoxorubicin plus paclitaxel combination (ET) vs single agent paclitaxel (T), as second-line chemotherapy treatment in advanced ovarian cancer patients in early progression within 12 months after platinum-based chemotherapy. From October 1994 up to...

Descripción completa

Detalles Bibliográficos
Autores principales: Buda, A, Floriani, I, Rossi, R, Colombo, N, Torri, V, Conte, P F, Fossati, R, Ravaioli, A, Mangioni, C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409494/
https://www.ncbi.nlm.nih.gov/pubmed/15150623
http://dx.doi.org/10.1038/sj.bjc.6601787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409494/
https://www.ncbi.nlm.nih.gov/pubmed/15150623
http://dx.doi.org/10.1038/sj.bjc.6601787

Ejemplares similares